95 completed, 52 recruiting, 48 active not recruiting, 30 terminated. 168 Phase 2, 64 Phase 1, 27 Phase 3, 4 Phase 4, 2 Not applicable.
Follow cabozantinib: new trials by email Literature Review of cabozantinib trials Research Report on cabozantinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-08-18 |
| Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 | Recruiting | Girish Dhall, MD | 30 | 2026-06-09 | 2026-10-02 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) Pumitamig, Ipilimumab, Cabozantinib - Advanced Renal Cell Carcinoma (RCC) | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 474 | 2026-03-26 | 2026-10-23 |
| Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Belzutifan, Nivolumab, Lenvatinib - Von Hippel-Lindau Disease, Malignant Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 450 | 2026-03-23 | 2026-10-21 |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer Biospecimen Collection, Cabozantinib, Cemiplimab - Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 48 | 2026-02-22 | 2026-09-18 |
| Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study Cabozantinib, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-02-12 | 2026-08-11 |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes Vincristine, Doxorubicin, Cyclophosphamide - Metastatic Ewing Sarcoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 15 | 2026-02-05 | 2026-09-25 |
| Cabozantinib Dose Skipping as an Alternative to Dose Reductions Cabozantinib - Renal Cell Carcinoma (RCC) | Phase 2 | Recruiting | dr. Tom van der Hulle | 34 | 2026-01-26 | 2026-08-31 |
| A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Belzutifan, Zanzalintinib, Cabozantinib - Renal Cell Carcinoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 904 | 2025-11-26 | 2026-08-03 |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 92 | 2025-11-17 | 2026-10-16 |
| Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma cabozantinib and nivolumab - Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma | Phase 4 | Recruiting | Centre Francois Baclesse | 83 | 2025-10-01 | 2026-07-14 |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma Casdatifan, Cabozantinib, Placebo - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | Arcus Biosciences, Inc. | 720 | 2025-09-08 | 2026-09-29 |
| Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy Cabozantinib - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | National Health Research Institutes, Taiwan | 60 | 2025-09-01 | 2025-09-03 |
| Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms | Phase 4 | Not yet recruiting | Fujian Medical University | 335 | 2025-07-01 | 2025-06-08 |
| Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma Nivolumab, Cabozantinib - Kidney Cancer, Renal Cell Cancer | Phase 4 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 50 | 2025-05-16 | 2025-09-24 |
| A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) Abemaciclib, Cabozantinib - Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 43 | 2025-02-14 | 2026-10-22 |
| Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate - Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Emory University | 21 | 2025-01-15 | 2026-02-18 |
| Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer Biospecimen Collection, Cabozantinib, Computed Tomography - Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 264 | 2024-12-27 | 2026-09-24 |
Showing 20 of 254. Sign in to see all of them.
Carcinoma, Renal Cell (71) · Carcinoma, Hepatocellular (26) · Prostatic Neoplasms (22) · Neoplasm Metastasis (19) · Neoplasms (19) · Carcinoma, Non-Small-Cell Lung (16) · Kidney Neoplasms (14) · Carcinoma, Medullary (9) · Carcinoma, Transitional Cell (9) · Colorectal Neoplasms (9) · Neuroendocrine Tumors (9) · Osteosarcoma (9) · Sarcoma (8) · Brain Neoplasms (7) · Breast Neoplasms (7)
National Cancer Institute (NCI) (38) · Exelixis (18) · M.D. Anderson Cancer Center (14) · Dana-Farber Cancer Institute (8) · Bristol-Myers Squibb (7) · Massachusetts General Hospital (6) · Memorial Sloan Kettering Cancer Center (6) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (5) · Emory University (4) · Hoffmann-La Roche (4) · Ipsen (4) · Takeda (4) · University of Utah (4) · Johannes Gutenberg University Mainz (3) · Merck Sharp & Dohme LLC (3)
United States (187) · Italy (41) · France (37) · Spain (37) · Canada (36) · Germany (34) · Australia (28) · United Kingdom (28) · Netherlands (22) · South Korea (22) · Belgium (21) · Japan (19) · Poland (19) · Czechia (17) · Argentina (15)
Joel W Neal (3) · Sara Tolaney, MD, MPH (3) · Andrea B Apolo (2) · Bhavana Konda (2) · Farshid Dayyani, MD, PhD (2) · Giuseppe Procopio, MD (2) · Salah-Eddin Al-Batran, Prof. Dr. (2) · Sumanta K Pal (2) · A P Chen (1) · Aaron Scott, MD (1)
PMID 26406150, PMID 27279544, PMID 37146227, PMID 19097774, PMID 23533264, PMID 27400947, PMID 27825636, PMID 28199818, PMID 28755607, PMID 29377755, PMID 31371341, PMID 31401903, PMID 33058158, PMID 35031545, PMID 35304832, PMID 35383907, PMID 37185961, PMID 10673991, PMID 12902325, PMID 15588232, PMID 16773629, PMID 16801334, PMID 16932650, PMID 17167516, PMID 17997439, PMID 18362143, PMID 18777528, PMID 18810319, PMID 19455472, PMID 19457631, PMID 21306237, PMID 21351269, PMID 21436587, PMID 21555688, PMID 21606412, PMID 22327622, PMID 22327623, PMID 22327624, PMID 22826385, PMID 23150706, PMID 23169517, PMID 23553848, PMID 23584301, PMID 23770567, PMID 23964934, PMID 2406025, PMID 24405892, PMID 24472710, PMID 24476821, PMID 24510426
U10CA180821 (11), 2019 (8), 2018 (6), 2023 (4), P30CA138292 (4), U10CA180820 (4), U10CA180888 (4), 2025 (3), U10CA180868 (3), 2017 (2), N01CM00038 (2), P30CA033572 (2), U10CA031946 (2), U10CA180886 (2), UM1CA186644 (2)